Sex and Gender Differences in Drug Response as an Underused Variable in Precision Medicine
Integrative Biomedical Research · 2026
DOI: 10.25163/biomedical.10110916 ↗Kurz gefasst
Fachartikel in der Zeitschrift Integrative Biomedical Research, 2026.
Abstract (Originalsprache)
Modern pharmacotherapy still relies, more often than clinicians acknowledge, on a male-default template inherited from decades of trial design rather than biological rationale. Growing pharmacovigilance and mechanistic evidence indicates that sex (biological) and gender (sociocultural) influence drug response through distinct, sometimes opposing, pathways—and that conflating the two carries real clinical consequences. This review addresses a deceptively simple question: how much of the disparity in drug efficacy and adverse drug events (ADEs) between men and women stems from biology versus the social context shaping how symptoms are noticed, reported, and treated? We performed a narrative synthesis of peer-reviewed literature, primarily 2022–2026, drawing on pharmacovigilance datasets, individual patient data meta-analyses, cohort studies, and mechanistic pharmacology research across oncology, psychiatry, nephrology, rheumatology, and substance-use epidemiology. Females consistently reported higher rates of non-serious, subjective adverse events, but this gap narrowed—and reversed for fatal outcomes—once severity was accounted for, a pattern consistent with the "Gender Hypothesis" of differential reporting. Biological mechanisms proved equally important: cytochrome P450 variation, body composition, and hormonal status altered clearance and toxicity across chemotherapeutics, antipsychotics, and immunomodulators, while premenopausal estrogen exposure appeared to blunt antimanic drug-placebo separation. Clinical risk calculators for acute kidney injury applied sex inconsistently or omitted it entirely, despite converging evidence of hormonally mediated renal protection. Sex and gender function as separable, interacting determinants of drug response, and neither substitutes for the other in clinical reasoning. Embedding sex-stratified analysis and SAGER-compliant reporting into trial design and pharmacovigilance infrastructure is not merely an equity concern—it is a prerequisite for pharmacological precision.
Zitieren
APA
(2026). Sex and Gender Differences in Drug Response as an Underused Variable in Precision Medicine. Integrative Biomedical Research. https://doi.org/10.25163/biomedical.10110916
Vancouver
Sex and Gender Differences in Drug Response as an Underused Variable in Precision Medicine. Integrative Biomedical Research. 2026. doi:10.25163/biomedical.10110916
BibTeX
@article{euvimed2026,
title = {Sex and Gender Differences in Drug Response as an Underused Variable in Precision Medicine},
journal = {Integrative Biomedical Research},
year = {2026},
doi = {10.25163/biomedical.10110916}
}
EUVIMED